Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kai Wucherpfennig, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Kai Wucherpfennig and Michael Dougan.
Connection Strength

1.306
  1. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell. 2021 03 18; 184(6):1575-1588.
    View in: PubMed
    Score: 0.957
  2. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell. 2020 08 06; 182(3):655-671.e22.
    View in: PubMed
    Score: 0.228
  3. cIAP1/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes. Sci Transl Med. 2021 05 19; 13(594).
    View in: PubMed
    Score: 0.061
  4. Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. Cancer Discov. 2021 Oct; 11(10):2564-2581.
    View in: PubMed
    Score: 0.060
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.